These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
500 related articles for article (PubMed ID: 28960207)
1. BH3 mimetics efficiently induce apoptosis in mouse basophils and mast cells. Reinhart R; Rohner L; Wicki S; Fux M; Kaufmann T Cell Death Differ; 2018 Jan; 25(1):204-216. PubMed ID: 28960207 [TBL] [Abstract][Full Text] [Related]
2. Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling. Peperzak V; Slinger E; Ter Burg J; Eldering E Cell Death Differ; 2017 Jan; 24(1):111-119. PubMed ID: 27689871 [TBL] [Abstract][Full Text] [Related]
3. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy. Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472 [TBL] [Abstract][Full Text] [Related]
4. BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines. Merino D; Kelly GL; Lessene G; Wei AH; Roberts AW; Strasser A Cancer Cell; 2018 Dec; 34(6):879-891. PubMed ID: 30537511 [TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival. Eichhorn JM; Alford SE; Sakurikar N; Chambers TC Exp Cell Res; 2014 Apr; 322(2):415-24. PubMed ID: 24556425 [TBL] [Abstract][Full Text] [Related]
6. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. Thijssen R; Diepstraten ST; Moujalled D; Chew E; Flensburg C; Shi MX; Dengler MA; Litalien V; MacRaild S; Chen M; Anstee NS; Reljić B; Gabriel SS; Djajawi TM; Riffkin CD; Aubrey BJ; Chang C; Tai L; Xu Z; Morley T; Pomilio G; Bruedigam C; Kallies A; Stroud DA; Bajel A; Kluck RM; Lane SW; Schoumacher M; Banquet S; Majewski IJ; Strasser A; Roberts AW; Huang DCS; Brown FC; Kelly GL; Wei AH Blood; 2021 May; 137(20):2721-2735. PubMed ID: 33824975 [TBL] [Abstract][Full Text] [Related]
7. Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs. Diepstraten ST; Young S; La Marca JE; Wang Z; Kluck RM; Strasser A; Kelly GL Cell Death Differ; 2023 Apr; 30(4):1005-1017. PubMed ID: 36755070 [TBL] [Abstract][Full Text] [Related]
8. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer. Merino D; Lok SW; Visvader JE; Lindeman GJ Oncogene; 2016 Apr; 35(15):1877-87. PubMed ID: 26257067 [TBL] [Abstract][Full Text] [Related]
9. A direct comparison of selective BH3-mimetics reveals BCL-X Bierbrauer A; Jacob M; Vogler M; Fulda S Br J Cancer; 2020 May; 122(10):1544-1551. PubMed ID: 32203216 [TBL] [Abstract][Full Text] [Related]
10. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia. Besbes S; Pocard M; Mirshahi M; Billard C Crit Rev Oncol Hematol; 2016 Apr; 100():32-6. PubMed ID: 26899021 [TBL] [Abstract][Full Text] [Related]
11. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF Hartman ML; Gajos-Michniewicz A; Talaj JA; Mielczarek-Lewandowska A; Czyz M Cancer Lett; 2021 Feb; 499():122-136. PubMed ID: 33259900 [TBL] [Abstract][Full Text] [Related]
12. Proapoptotic Bcl-2 family member Bim is involved in the control of mast cell survival and is induced together with Bcl-XL upon IgE-receptor activation. Alfredsson J; Puthalakath H; Martin H; Strasser A; Nilsson G Cell Death Differ; 2005 Feb; 12(2):136-44. PubMed ID: 15592435 [TBL] [Abstract][Full Text] [Related]
14. The BH3-mimetic ABT-737 induces mast cell apoptosis in vitro and in vivo: potential for therapeutics. Karlberg M; Ekoff M; Huang DC; Mustonen P; Harvima IT; Nilsson G J Immunol; 2010 Aug; 185(4):2555-62. PubMed ID: 20639495 [TBL] [Abstract][Full Text] [Related]
15. Potential mechanisms of resistance to venetoclax and strategies to circumvent it. Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655 [TBL] [Abstract][Full Text] [Related]
16. It's time to die: BH3 mimetics in solid tumors. Kehr S; Vogler M Biochim Biophys Acta Mol Cell Res; 2021 Apr; 1868(5):118987. PubMed ID: 33600840 [TBL] [Abstract][Full Text] [Related]
17. Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family members. Opferman JT FEBS J; 2016 Jul; 283(14):2661-75. PubMed ID: 26293580 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma. Zhang Y; Ishida CT; Shu C; Kleiner G; Sanchez-Quintero MJ; Bianchetti E; Quinzii CM; Westhoff MA; Karpel-Massler G; Siegelin MD Sci Rep; 2018 May; 8(1):7373. PubMed ID: 29743557 [TBL] [Abstract][Full Text] [Related]
19. BH3 mimetics: status of the field and new developments. Billard C Mol Cancer Ther; 2013 Sep; 12(9):1691-700. PubMed ID: 23974697 [TBL] [Abstract][Full Text] [Related]
20. Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling. Grundy M; Seedhouse C; Jones T; Elmi L; Hall M; Graham A; Russell N; Pallis M PLoS One; 2018; 13(1):e0190682. PubMed ID: 29298347 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]